A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.
Also called NCT05785832
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 319 participants
- Registry
-
NCT05785832
-
- Main results
- A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
- Other papers using this trial's data
- Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
- Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level
- Consistent Benefit of Control-IQ+ Automated Insulin Delivery Across a Range of Characteristics of Adults with Type 2 Diabetes
- Simplified Meal Bolus Strategies with Control-IQ+ Automated Insulin Delivery Are Safe and Effective in Adults with Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT05785832. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (actual); primary completion 2024-09-24 (actual). Results posted on 2025-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
- Acronym
- 2IQP
- Condition
- Type 2 Diabetes Treated With Insulin
- Intervention (Device)
- t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM
- Intervention (Device)
- Standard Therapy plus continuous glucose monitoring (CGM)
- Lead sponsor
- Tandem Diabetes Care, Inc.
- Collaborator
- Jaeb Center for Health Research
Record details
- Record id
cardio:ct-nct05785832- Content hash
f8415afac692cd962920bd8944903924c8b639f999fd29fc9e00822a16c987bd